UCB, Roche to develop antibodies for Alzheimer's disease

By The Science Advisory Board staff writers

July 29, 2020 -- Biopharmaceutical firm UCB has signed a deal to provide Roche and Genentech with an exclusive, worldwide license to its UCB0107 antitau antibody treatment for people living with Alzheimer's disease.

In addition to receiving an initial upfront payment of $120 million, UCB will also receive, after positive completion of a proof-of-concept study in Alzheimer's disease, further payments with a total potential consideration approaching $2 billion upon receipt of certain regulatory approvals and satisfying certain milestones, according to the vendor.

UCB noted that it will fund and perform the initial proof-of-concept study for the investigational monoclonal antibody drug in Alzheimer's disease. Once the study has been completed and results are available, Genentech will then have the right to proceed with clinical development or return full rights back to UCB, the company said.

Animal study turns in positive results for Moderna-NIH COVID-19 vaccine
Moderna's COVID-19 vaccine candidate, messenger RNA (mRNA)-1273, has been shown to induce immune responses and control upper and lower respiratory tract...
Extracellular RNA identifies new Alzheimer's biomarker
The association of extracellular RNA with upregulation of the phosphoglycerate dehydrogenase gene may be a useful presymptomatic biomarker for Alzheimer's...
Small-molecule chaperones may reverse Alzheimer's symptoms in mice
A novel treatment for Alzheimer's disease involving the administration of pharmacological chaperones that prevent amyloid beta and tau tangles from forming...
New genetic risk factor discovered for Alzheimer's disease
A new genetic risk factor for late-onset Alzheimer's disease (LOAD) has been identified by researchers from the University of Kentucky. The results of...
New molecular cause identified for neurodegeneration in Alzheimer's disease
A collaborative research effort uncovered evidence for a new molecular basis for neurodegeneration seen in patients with Alzheimer's disease. Researchers...

Copyright © 2020 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Conferences
2020 ACCP Annual Meeting
September 20-22
Bethesda, Maryland United States
Bioprocess International West
September 21-24
Eastern Standard Time Zone (EST) United States
BioProcess International
September 21-24
Eastern Standard Time Zone (EST), Massachusetts United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter